WO2013018481A1 - Préparation cosmétique externe pour la peau et son procédé de production, composition comprenant un sel de 2-phosphate-6-(ester d'acide gras supérieur) d'ascorbyle et un tensioactif non ionique - Google Patents

Préparation cosmétique externe pour la peau et son procédé de production, composition comprenant un sel de 2-phosphate-6-(ester d'acide gras supérieur) d'ascorbyle et un tensioactif non ionique Download PDF

Info

Publication number
WO2013018481A1
WO2013018481A1 PCT/JP2012/066826 JP2012066826W WO2013018481A1 WO 2013018481 A1 WO2013018481 A1 WO 2013018481A1 JP 2012066826 W JP2012066826 W JP 2012066826W WO 2013018481 A1 WO2013018481 A1 WO 2013018481A1
Authority
WO
WIPO (PCT)
Prior art keywords
ascorbyl
skin preparation
external skin
phosphate
fatty acid
Prior art date
Application number
PCT/JP2012/066826
Other languages
English (en)
Inventor
Naoko Ito
Original Assignee
Showa Denko K.K.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Showa Denko K.K. filed Critical Showa Denko K.K.
Publication of WO2013018481A1 publication Critical patent/WO2013018481A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers

Definitions

  • the present invention relates to an external skin preparation and a method for producing the same.
  • vitamin C Ascorbic acid (vitamin C) and various derivatives thereof are known to be
  • ascorbic acid derivatives ascorbyl 2-phosphate derivatives, in which a hydroxyl group at position 2 of ascorbic acid is converted to a phosphate ester, are particularly preferred.
  • ascorbyl 2-phosphate derivatives include ascorbyl 2-phosphate and ascorbyl 2-phosphate-6-higher fatty acids in which a hydroxyl group at position 6 thereof is esterified by a higher fatty acid such as palmitic acid and these are normally used in the form of salts.
  • salts include sodium salts or magnesium salts of ascorbyl 2-phosphate and sodium salts of ascorbyl 2-phosphate-6-higher fatty acids.
  • ascorbyl 2-phosphate-6-higher fatty acid salts are amphiphilic, they demonstrate high affinity for the body and rapidly migrate to body tissue such as the skin, and are expected to be applied to cosmetics and other external skin preparations.
  • Decomposition of ascorbyl 2-phosphate-6-higher fatty acid salts is mainly caused by hydrolysis of the higher fatty acid esterbonded to the hydroxyl group at position 6 of ascorbic acid.
  • water-insoluble higher fatty acid salts such as sodium palmitate form and appear as a precipitate in the preparation.
  • these precipitates are unable to be confirmed visually in turbid drug forms such as creams, in the case of clear lotions or beauty essences and the like, problems caused by changes in appearance occur in the form of turbidity and precipitation.
  • Patent Document 1 discloses a method that comprises the
  • incorporation of a water-soluble synthetic polymer compound such as carboxyvinyl polymer and water as a method for stabilizing an external skin preparation containing an ascorbyl 2-phosphate-6-higher fatty acid salt. According to this method, decomposition and a resulting reduction in the ascorbyl 2-phosphate-6-higher fatty acid salt in the external skin preparation are inhibited, thereby making it possible to inhibit the occurrence of coloration and precipitation of the external skin preparation over time.
  • Patent Document 2 discloses a method comprising the incorporation of a polyvalent alcohol as a method for stabilizing an external skin preparation containing an ascorbyl 2-phosphate-6-higher fatty acid salt. According to this method, the occurrence of turbidity and precipitation of the external skin preparation over time can be inhibited.
  • Patent Document 3 discloses a method for making an average emulsion particle diameter be in a range from 1 to 200 nm by using a polyglycerin fatty acid ester containing polyglycerin having an average degree of polymerization of 8 to 12 and an unsaturated fatty acid residue having 14 to 22 carbon atoms, and a polyglycerin mono fatty acid ester containing polyglycerin having an average degree of polymerization of 2 to 6 and an unsaturated fatty acid residue having 14 to 22 carbon atom, as an emulsifier, as a method for stabilizing an external skin preparation containing an ascorbyl
  • 2-phosphate-6-higher fatty acid salt According to this method, decomposition of the ascorbyl 2-phosphate-6-higher fatty acid salt in the external skin preparation is inhibited, storage stability is also improved, and an attractive transparent to semi-transparent appearance can be maintained.
  • Patent Document 4 proposes the incorporation of at least one type of a component A: storage stabilizer, organic acid having a chelating effect or salt thereof, a component B: nonionic surfactant, a component C: ascorbic acid, derivative thereof or salt thereof, and a component D: ultraviolet protector, in order to enhance the stability of a composition containing fullerene, a derivative thereof, an inclusion compound or a salt thereof that has poor stability on its own.
  • Patent Document 4 is a method for improving the stability of fullerenes, is not a method for improving the stability of an ascorbyl
  • 2-phosphate-6-higher fatty acid salt per se may impair stability of an ascorbyl 2-phosphate- 6-higher fatty acid salt.
  • Patent Document 1 Japanese Unexamined Patent Application, First Publication No. 2005-187466
  • Patent Document 2 Japanese Unexamined Patent Application, First Publication No. 2005-336156
  • Patent Document 3 Japanese Unexamined Patent Application, First Publication No. 2008-13464
  • Patent Document 4 Japanese Unexamined Patent Application, First Publication No. 2004-269523
  • an object of the present invention is to provide an external skin preparation that contains an ascorbyl 2-phosphate-6-higher fatty acid salt and has superior preparation stability, and a production method thereof.
  • the inventor of the present invention found that the aforementioned object is achieved by combining a specific nonionic surfactant with an ascorbyl 2-phosphate-6- higher fatty acid salt, thereby leading to completion of the present invention.
  • the present invention has the aspects described below.
  • a nonionic surfactant (1) represented by the following formula (1):
  • R 1 represents a linear or branched alkyl group
  • R 2 represents -CH 2 CH(CH 3 )- or -CH(CH 3 )CH 2 -, and m and n are each positive integers
  • R 3 represents -CH 2 CH(CH3)- or -CH(CH3)CH 2 -, and a, b and c are each positive integers].
  • a production method of an external skin preparation including:
  • R represents a l
  • R represents -CH 2 CH(CH 3 )- or -CH(CH3)CH 2 -
  • m and n are each positive integers] wherein the average value of m in formula (1) is 2 to 25, and the average value of n is 3 to 34.
  • R 3 represents -CH 2 CH(CH 3 )- or -CH(CH 3 )C3 ⁇ 4-, and a, b and c are each positive integers].
  • an external skin preparation which contains an ascorbyl 2-phosphate-6-higher fatty acid salt and has superior preparation stability, and a production method thereof, can be provided.
  • the ascorbyl 2-phosphate-6-higher fatty acid salt is a compound that has formed a salt with an anion and a counter ion, the anion being formed by phosphoric acid being ester-bonded to a hydroxyl group bonded to a carbon atom at position 2 of ascorbic acid, a higher fatty acid being ester-bonded to a hydroxyl group bonded to a carbon atom at position 6, and dissociation of at least one of the hydrogen atoms of the two hydroxyl groups bound to the phosphorous atom in the phosphate group and the hydroxyl group bonded to the carbon atom at position 3 of ascorbic acid, an example of which is a salt of a counter ion and an anion represented by the structural formula indicated below.
  • a higher fatty acid refers to a fatty acid having 11 or more carbon atoms.
  • the number of carbon atoms of the aforementioned higher fatty acid is preferably 12 to 28 in consideration of handling ease as an ascorbyl 2-phosphate-6-higher fatty acid salt.
  • the aforementioned counter ion is preferably an alkaline metal ion.
  • an alkaline metal salt is preferable for the ascorbyl 2-phosphate-6-higher fatty acid salt.
  • alkaline metals include sodium and potassium.
  • an ascorbyl 2-phosphate derivative other than an ascorbyl 2-phosphate-6- higher fatty acid salt may be incorporated in the external skin preparation of the present invention, when only an ascorbyl
  • 2-phosphate-6-higher fatty acid salt is incorporated for the ascorbyl 2-phosphate derivative, decomposition of the ascorbyl 2-phosphate-6-higher fatty acid salt is further inhibited, stability of the preparation improves, and there is less susceptibility to increases in coloration, precipitation and the like.
  • 2-phosphate-6-palmitate is preferable, an alkaline metal salt of an ascorbyl
  • 2-phosphate-6-higher fatty acid salt is more preferable, a sodium ascorbyl
  • 2-phosphate-6-higher fatty acid salt is even more preferable, and sodium ascorbyl 2-phosphate-6-palmitate is particularly preferable for the ascorbyl 2-phosphate-6-higher fatty acid salt.
  • ascorbyl 2-phosphate-6-higher fatty acid salt may be used alone or two or more types may be used in combination.
  • the incorporated amount of the ascorbyl 2-phosphate-6-higher fatty acid salt in the total amount of the external skin preparation is preferably 0.01% by mass to 10% by mass and more preferably 0.5% by mass to 5% by mass. If the incorporated amount is 0.01% by mass or more, the ascorbyl 2-phosphate-6-higher fatty acid salt rapidly migrates to the skin when the external skin preparation of the present invention is applied to the skin, thereby enabling the actions and effects required of the external skin preparation to be adequately demonstrated. Greater effects are not necessarily obtained if incorporated in excess of 10% by mass, thereby making this uneconomical.
  • the external skin preparation of the present invention contains a nonionic surfactant (1) represented by the following formula ( 1 ) :
  • R represents a linear or branched alkyl group
  • R represents -CH 2 CH(CH 3 )- or -CH(CH3)CH 2 -
  • m and n are each positive integers
  • the nonionic surfactant (1) is a POE-POP alkyl ether in which a linear or branched alkyl alcohol and a polyoxyethylene (POE) chain (CH 2 CH 2 0) n ) are ether-bonded, and a polyoxypropylene (POP) chain ((R 0) m ) is ether-bonded to the linear or branched alkyl chain and the POE chain.
  • POE polyoxyethylene
  • POP polyoxypropylene
  • R 1 represents a linear or branched alkyl group.
  • the alkyl group of R 1 may be linear or branched, the degree of branching is preferably low, and an alkyl group that is branched at one location or a linear alkyl group is preferable.
  • the number of carbon atoms of R 1 it is preferably 8 to 30, more preferably 10 to 26 and even more preferably 16 to 24.
  • examples include a decyl group, lauryl group, cetyl group, stearyl group and decyltetradecyl group.
  • m indicates the number (degree of
  • n indicates the number (degree of
  • the average value of m namely the number (average degree of polymerization) of an oxypropylene group per molecule of the nonionic surfactant (1) is 2 to 25, preferably 3 to 25 and more preferably 5 to 34.
  • the average value of n namely the number (average degree of polymerization) of an oxyethylene group per molecule of the nonionic surfactant (1) is 3 to 34, preferably 6 to 12 and even more preferably 3 to 34. If the values of m and n are each within the aforementioned ranges, preparation stability of the external skin preparation is adequately obtained.
  • the ratio of m/n is preferably 0.05 to 20 and more preferably 0.2 to 1.
  • nonionic surfactant (1) examples include, but are not limited to, POE(4)POP(2) decyl ether, POE(7)POP(2) decyl ether, POE(8)POP(2) decyl ether, POE(10)POP(2) decyl ether, POE(15)POP(2) decyl ether, POE(20)POP(2) decyl ether, POE(30)POP(2) decyl ether, POE(40)POP(2) decyl ether, POE(8)POP(2) lauryl ether, POE(15)POP(4) lauryl ether, POE(10)POP(4) cetyl ether, POE(20)POP(4) cetyl ether, POE(20)POP(8) cetyl ether, POE(20)POP(6) decyltetradecyl ether and POE(30)POP(6) decyltetradecyl ether.
  • POE(4)POP(2) decyl ether POE
  • POE(20)POP(8) cetyl ether, POE(12)POP(6) decyltetradecyl ether, POE(20)POP(6) decyltetradecyl ether, and POE(30)POP(6) decyltetradecyl ether are preferable.
  • values shown in parentheses following POE indicate the average degree of polymerization of the POE chain (namely, the average number of n in the aforementioned formula (1)).
  • Values shown in parentheses following POP indicate the average degree of polymerization of the POP chain (namely, the average value of m in the aforementioned formula (1)).
  • the nonionic surfactant (1) may be produced according to a known production method or a commercially available product may be used.
  • commercially available products include members of the Emalex series (trade name, Nihon Emulsion Co., Ltd.), members of the Noygen series (trade name, Dai-Ichi Kogyo Seiyaku Co., Ltd.), and members of the NIKKOL PBC series and NIKKOL PEN series (trade names, Nikko Chemicals Co., Ltd.).
  • the nonionic surfactant (1) may be used alone or two or more types may be used in combination.
  • the content of the nonionic surfactant (1) in the total amount of the external skin preparation is preferably 0.1% by mass to 10% by mass and preferably 0.5% by mass to 2% by mass. If the content of the nonionic surfactant (1) is 0.1% by mass or more, the resulting preparation has superior stability and is not susceptible to the occurrence of precipitation and turbidity during storage. Greater effects are not necessarily obtained if incorporated in excess of 10% by mass, thereby making this uneconomical.
  • the external skin preparation of the present invention preferably further contains a nonionic surfactant (2) represented by the following formula (2):
  • R represents -CH 2 CH(CH 3 )- or -CH(CH 3 )CH 2 -, and a, b and c are each positive integers].
  • the nonionic surfactant (2) is a POE-POP glycol having the structure of a
  • POE-POP-POE block copolymer in which a POP chain is ether-bonded between POE chains (to be referred to as a POE-POP-POE type).
  • nonionic surfactant (2) further improves preparation stability of the external skin preparation over a wide temperature range from low temperatures to high temperatures.
  • the average value of a + c namely the number (average degree of polymerization) of the oxyethylene group per molecule of the nonionic surfactant (2) is preferably 4 to 400 and more preferably 20 to 160.
  • the average value of b namely the number (average degree of polymerization) of the oxypropylene group per molecule of the nonionic surfactant (2) is preferably 5 to 70 and more preferably 20 to 50. If the values of (a + c) and b are each within the
  • the effect of improving preparation stability of the external skin preparation is superior.
  • the average value of a + b + c namely the total number of the oxypropylene group and the oxyethylene group per molecule of the nonionic surfactant (2), is preferably 7 to 470 and more preferably 20 to 100.
  • the ratio of (a + c)/b is preferably 0.05 to 80 and more preferably 0.3 to 3.
  • nonionic surfactant (2) examples include, but are not limited to, POE(5)POP(5) glycol, POE(5)POP(30) glycol, POE(10)POP(8) glycol, POE(16)POP(17) glycol, POE(20)POP(20) glycol, POE(25)POP(30) glycol, POE(35)POP(40) glycol, POE(100)POP(40) glycol, POE(300)POP(55) glycol and POE(400)POP(70) glycol.
  • POE(25)POP(30) glycol and POE(35)POP(40) glycol are more preferably from the viewpoint of preparation stability of the external skin preparation.
  • the nonionic surfactant (2) may be produced according to a known production method or a commercially available product may be used.
  • commercially available products include members of the Adeka Pluronic L series, Adeka Pluronic P series and Adeka Pluronic F series (trade names, Adeka Corp.), as well as members of the Newpol PE series (trade name, Sanyo Chemical Industries, Ltd.).
  • the nonionic surfactant (2) may be used alone or two or more types may be used in combination.
  • the content of the nonionic surfactant (2) in the total amount of the external skin preparation is preferably 0.1% by mass to 10% by mass and preferably 0.5% by mass to 2% by mass. If the content of the nonionic surfactant (2) is 0.1% by mass or more, the effect of incorporating the nonionic surfactant (2) is adequately obtained. Greater effects are not necessarily obtained if incorporated in excess of 10% by mass, thereby making this uneconomical.
  • the external skin preparation of the present invention may also incorporate at least one type selected from the group consisting of ascorbic acid and salts thereof as well as ascorbic acid derivatives other than ascorbyl 2-phosphate-6- higher fatty acid salts.
  • salts of ascorbic acid include sodium salts and potassium salts.
  • Examples of ascorbic acid derivatives other than ascorbyl 2-phosphate-6-higher fatty acid salts include ascorbyl 2-phosphoric acid and salts thereof, ascorbyl 3-phosphate- 6-higher fatty acids and salts thereof, ascorbyl 6-higher fatty acids and salts thereof, ascorbyl 2,6-di-higher fatty acids and salts thereof, ascorbyl 2,3,5,6-tetra-higher fatty acids and salts thereof, ascorbyl 2-sulfuric acid and salts thereof and ascorbyl 2-glucosides.
  • Examples of salts include sodium salts and potassium salts.
  • Examples of higher fatty acids include fatty acids having 8 to 22 carbon atoms.
  • the external skin preparation of the present invention preferably only incorporates the aforementioned ascorbyl 2-phosphate-6-higher fatty acid salt for the ascorbyl 2-phosphate derivative.
  • the external skin preparation of the present invention preferably does not incorporate an ascorbyl 2-phosphate derivative other than the ascorbyl 2-phosphate-6-higher fatty acid salt. According to studies conducted by the inventor of the present invention, incorporating only the ascorbyl 2-phosphate-6-higher fatty acid salt more effectively inhibits decomposition of the ascorbyl
  • 2-phosphate-6-higher fatty acid salt and more easily improves preparation stability than incorporating the ascorbyl 2-phosphate-6-higher fatty acid salt with another ascorbyl 2-phosphate derivative. Namely, more superior preparation stability is obtained by not incorporating an ascorbyl 2-phosphate derivative other than the ascorbyl
  • an ascorbyl 2-phosphate derivative refers to an ascorbic acid derivative in which phosphoric acid is ester-bonded to at least the hydroxyl group bonded to the carbon atom at position 2 of ascorbic acid.
  • examples of ascorbyl 2-phosphate derivatives other than the ascorbyl are examples of ascorbyl 2-phosphate derivatives other than the ascorbyl
  • 2-phosphate-6-higher fatty acid salt include ascorbyl 2-phosphoric acid and salts thereof.
  • the ascorbyl Furthermore, within the external skin preparation, the ascorbyl
  • 2-phosphate-6-higher fatty acid salt may decompose to form a higher fatty acid and ascorbyl 2-phosphoric acid. Consequently, a trace amount of ascorbyl 2-phosphoric acid or salt thereof may be contained in the external skin preparation of the present invention even if it is not incorporated during production.
  • the phosphate group at position 2 of the ascorbyl 2-phosphate-6-higher fatty acid salt may transpose to position 3 over time.
  • the external skin preparation of the present invention may also contain components normally used in external skin preparations within a range that does not impair the effects of the present invention, examples of which include carries and additives
  • Such components include hydrocarbons, natural fats and oils, fatty acids, higher alcohols, alkyl glyceryl ethers, esters, silicone oils, polyvalent alcohols, monovalent lower alcohols, sugars, polymers, anionic surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants not corresponding to the aforementioned nonionic surfactants (1) and (2), natural surfactants, ultraviolet absorbers, powders, colorants, amino acids, peptides, vitamins, vitamin-like effectors, antiseptics, antioxidants, metal ion sequestering agents, moisturizers, antiphlogistics, pH adjusters, salts, organic acids, whitening agents, essential oils, terpenes, fragrances and water.
  • Examples of the external skin preparation of the present invention include cosmetics and pharmaceuticals.
  • the external skin preparation of the present invention is a cosmetic
  • known cosmetic raw materials can be further added at typical concentrations.
  • all cosmetic raw materials can be used that are described in the Second Edition of the Japanese Standards of Cosmetic Ingredients, Pharmaceutical and Medical Device Regulatory Science Society of Japan ed., 1984 (Yakuji Nippo Ltd.), Japanese Cosmetic Ingredients Codex, Ministry of Health, Labour and Welfare, Pharmaceutical Affairs Bureau, Inspection Section, ed., 1993 (Yakuji Nippo Ltd.), Supplement to the Japanese Cosmetic Ingredients Codex, Ministry of Health, Labour and Welfare, Pharmaceutical Affairs Bureau, Inspection Section, ed., 1993 (Yakuji Nippo Ltd.), Comprehensive Licensing Standards of Cosmetics by Category, Ministry of Health, Labour and Welfare, Pharmaceutical Affairs Bureau, Inspection Section, ed., 1993 (Yakuji Nippo Ltd.), Categorized Japanese Cosmetic Ingredients Codex, Ministry of Health, Labour and Welfare, Pharmaceutical Affairs Bureau, Inspection Section, ed., 1997 (Yakuji Nippo Ltd.) and the Encyclopedia of Chemical Raw Materials, 1991
  • the external skin preparation of the present invention is used by contacting the skin at the time of use, and is suitably determined corresponding to the application.
  • forms that can be applied include a lotion, milky liquid, cream or facial pack.
  • preparation of the present invention demonstrates the effects thereof particularly when in the form of a lotion in which precipitation is conspicuous.
  • the pH of the external skin preparation of the present invention is preferably 6.5 to 7.5. If the pH is within this range, stability of the ascorbyl 2-phosphate-6-higher fatty acid salt is favorable and preparation stability is also more favorable. Furthermore, the pH refers to the value at about 25°C.
  • the external skin preparation of the present invention is produced by incorporating and formulating an ascorbyl 2-phosphate-6-higher fatty acid salt, the nonionic surfactant (1) and other arbitrary components.
  • an ascorbyl 2-phosphate derivative other than the ascorbyl 2-phosphate-6- higher fatty acid salt is preferably not incorporated.
  • Formulation can be carried out in accordance with ordinary methods corresponding to the form of the preparation.
  • the external skin preparation of the present invention is useful over the entire range of external skin preparations, including cosmetics and pharmaceuticals, and is particularly useful in cosmetics.
  • the resulting lotions were evaluated using the following procedures for the occurrence of turbidity and precipitation immediately after preparation and after storing for one month.
  • the lotions were stored by allowing to stand undisturbed at 4°C, 25°C or 40°C. These results are also shown in Table 1.
  • Turbidity was evaluated visually according to the following evaluation criteria. -: No turbidity observed
  • Examples 7 and 8, Comparative Examples 5 to 10 and Reference Example A Various components were uniformly dispersed and dissolved to obtain the compositions shown in Table 2 (units: % by mass) and then stirred to obtain lotions. The pH values (at 25 °C) of the lotions immediately after preparation thereof are also shown in Table 2.
  • Example 2 The resulting lotions were evaluated in the same manner as Example 1 (evaluation of turbidity and evaluation of precipitation). Those results are also shown in Table 2.
  • nonionic surfactant (1) inhibited the occurrence of turbidity and precipitation over time over a wider temperature range and demonstrated improved lotion stability in comparison with Comparative Examples 5 to 8 that incorporated an ester-type nonionic surfactant.
  • POE(7)POP(2) decyl ether EMALEX DAPE-0207, Nihon Emulsion Co., Ltd.
  • POE(8)POP(4) lauryl ether Noygen LP-100, Dai-Ichi Kogyo Seiyaku Co., Ltd.
  • POE(10)POP(4) cetyl ether NIKKOL PBC-33, Nikko Chemicals Co., Ltd.
  • POE(20) decyltetradecyl ether EMALEX 2420, Nihon Emulsion Co., Ltd.
  • Decaglyceryl monostearate NIKKOL Decaglynl-SV, Nikko Chemicals Co., Ltd.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une préparation externe pour la peau contenant un sel de 2-phosphate-6-(ester d'acide gras supérieur) d'ascorbyle. Cette composition présente une bonne stabilité. L'invention concerne également un procédé de production de la composition. La composition contient en outre un tensioactif non ionique (1) représenté par la formule (1) suivante : R1-O-(R2O)m-(CH2CH2O)n-H...(1), dans laquelle R1 représente un groupe alkyle linéaire ou ramifié, R2 représente -CH2CH(CH3)- ou -CH(CH3)CH2- et m et n représentent chacun des nombres entiers positifs, la valeur moyenne de m étant comprise entre 2 et 25, la valeur moyenne de n étant comprise entre 3 et 34.
PCT/JP2012/066826 2011-08-01 2012-06-26 Préparation cosmétique externe pour la peau et son procédé de production, composition comprenant un sel de 2-phosphate-6-(ester d'acide gras supérieur) d'ascorbyle et un tensioactif non ionique WO2013018481A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-168580 2011-08-01
JP2011168580A JP5865623B2 (ja) 2011-08-01 2011-08-01 皮膚外用剤およびその製造方法

Publications (1)

Publication Number Publication Date
WO2013018481A1 true WO2013018481A1 (fr) 2013-02-07

Family

ID=46598904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/066826 WO2013018481A1 (fr) 2011-08-01 2012-06-26 Préparation cosmétique externe pour la peau et son procédé de production, composition comprenant un sel de 2-phosphate-6-(ester d'acide gras supérieur) d'ascorbyle et un tensioactif non ionique

Country Status (2)

Country Link
JP (1) JP5865623B2 (fr)
WO (1) WO2013018481A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5865624B2 (ja) * 2011-08-01 2016-02-17 昭和電工株式会社 皮膚外用剤およびその製造方法
JP5865622B2 (ja) * 2011-08-01 2016-02-17 昭和電工株式会社 皮膚外用剤およびその製造方法
JP6851576B2 (ja) * 2016-04-20 2021-03-31 日立化成ダイアグノスティックス・システムズ株式会社 検体中の脂質による濁り抑制剤

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689830A2 (fr) * 1994-06-30 1996-01-03 Senju Pharmaceutical Co., Ltd. Composition cosmétique pour la peau
JP2004269523A (ja) 2003-02-20 2004-09-30 Shinobu Ito フラーレン外用組成物
JP2005187466A (ja) 2003-12-04 2005-07-14 Showa Denko Kk アスコルビン酸−２−リン酸エステルの高級脂肪酸エステルの塩を含む皮膚外用剤、該エステルの塩の安定化方法および安定化剤
JP2005187465A (ja) * 2003-12-04 2005-07-14 Showa Denko Kk アスコルビン酸−２−リン酸エステルの高級脂肪酸エステルの塩を含む乳化された皮膚外用剤、その製造方法、ならびに該エステル塩の安定化方法
EP1595936A1 (fr) * 2003-01-27 2005-11-16 Mitsubishi Corporation Composition antioxydante et composition a usage externe
JP2005336156A (ja) 2003-10-14 2005-12-08 Showa Denko Kk アスコルビン酸誘導体塩を含む皮膚外用剤、該皮膚外用剤の安定化方法および安定化剤
JP2006063060A (ja) * 2004-07-30 2006-03-09 Showa Denko Kk Ｌ−アスコルビン酸−２−リン酸エステルマグネシウムナトリウム塩、その製造方法および該塩を含有する化粧料
JP2007056009A (ja) * 2005-07-27 2007-03-08 Showa Denko Kk 乳化皮膚外用剤および該皮膚外用剤の安定化方法
JP2007320858A (ja) * 2006-05-30 2007-12-13 Nippon Menaade Keshohin Kk アスコルビン酸−２−リン酸エステル誘導体を含有する組成物
JP2008013464A (ja) 2006-07-04 2008-01-24 Showa Denko Kk エマルション組成物
JP2011168580A (ja) 2010-01-19 2011-09-01 Daiichi Sankyo Healthcare Co Ltd 医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE202694T1 (de) * 1993-07-01 2001-07-15 Yamanouchi Europ Bv Retinoid enthaltende stabile topische zusammensetzungen
JP2003176217A (ja) * 2001-12-12 2003-06-24 Showa Denko Kk 皮膚外用剤
JP4341983B2 (ja) * 2007-12-07 2009-10-14 株式会社資生堂 皮膚外用剤
JP5189836B2 (ja) * 2007-12-25 2013-04-24 ライオン株式会社 油分含有化粧料組成物
JP5865622B2 (ja) * 2011-08-01 2016-02-17 昭和電工株式会社 皮膚外用剤およびその製造方法
JP5865624B2 (ja) * 2011-08-01 2016-02-17 昭和電工株式会社 皮膚外用剤およびその製造方法

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689830A2 (fr) * 1994-06-30 1996-01-03 Senju Pharmaceutical Co., Ltd. Composition cosmétique pour la peau
EP1595936A1 (fr) * 2003-01-27 2005-11-16 Mitsubishi Corporation Composition antioxydante et composition a usage externe
JP2004269523A (ja) 2003-02-20 2004-09-30 Shinobu Ito フラーレン外用組成物
JP2005336156A (ja) 2003-10-14 2005-12-08 Showa Denko Kk アスコルビン酸誘導体塩を含む皮膚外用剤、該皮膚外用剤の安定化方法および安定化剤
JP2005187466A (ja) 2003-12-04 2005-07-14 Showa Denko Kk アスコルビン酸−２−リン酸エステルの高級脂肪酸エステルの塩を含む皮膚外用剤、該エステルの塩の安定化方法および安定化剤
JP2005187465A (ja) * 2003-12-04 2005-07-14 Showa Denko Kk アスコルビン酸−２−リン酸エステルの高級脂肪酸エステルの塩を含む乳化された皮膚外用剤、その製造方法、ならびに該エステル塩の安定化方法
JP2006063060A (ja) * 2004-07-30 2006-03-09 Showa Denko Kk Ｌ−アスコルビン酸−２−リン酸エステルマグネシウムナトリウム塩、その製造方法および該塩を含有する化粧料
JP2007056009A (ja) * 2005-07-27 2007-03-08 Showa Denko Kk 乳化皮膚外用剤および該皮膚外用剤の安定化方法
JP2007320858A (ja) * 2006-05-30 2007-12-13 Nippon Menaade Keshohin Kk アスコルビン酸−２−リン酸エステル誘導体を含有する組成物
JP2008013464A (ja) 2006-07-04 2008-01-24 Showa Denko Kk エマルション組成物
JP2011168580A (ja) 2010-01-19 2011-09-01 Daiichi Sankyo Healthcare Co Ltd 医薬組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia of Chemical Raw Materials", 1991, NIKKO CHEMICALS CO., LTD.
"Japanese Cosmetic Ingredients Codex, Ministry of Health, Labour and Welfare, Pharmaceutical Affairs Bureau, Inspection Section", 1993, YAKUJI NIPPO LTD
"Labour and Welfare, Pharmaceutical Affairs Bureau", 1993, YAKUJI NIPPO LTD.
"Pharmaceutical Affairs Bureau", 1993, YAKUJI NIPPO LTD.
"Pharmaceutical Affairs Bureau", 1997, YAKUJI NIPPO LTD.
"Pharmaceutical and Medical Device Regulatory Science Society of Japan", 1984, YAKUJI NIPPO LTD.

Also Published As

Publication number Publication date
JP2013032303A (ja) 2013-02-14
JP5865623B2 (ja) 2016-02-17

Similar Documents

Publication Publication Date Title
JP6057461B2 (ja) αゲル構造体およびそれを含有する化粧料または皮膚外用剤
JP2010120859A (ja) 皮膚用化粧料
WO2013018491A1 (fr) Préparation cosmétique externe pour la peau et son procédé de production, composition contenant un sel d'acide gras supérieur 2-phosphate-6 d'ascorbyle et un tensioactif non ionique
WO2006073190A1 (fr) Préparation à usage externe
WO2013018481A1 (fr) Préparation cosmétique externe pour la peau et son procédé de production, composition comprenant un sel de 2-phosphate-6-(ester d'acide gras supérieur) d'ascorbyle et un tensioactif non ionique
CN113784760B (zh) 凝胶状皮肤外用组合物
JP2013095691A (ja) 皮膚外用剤
CN109890361B (zh) 含有亚油酸的组合物
JP4095950B2 (ja) 皮膚外用剤
WO2013018457A1 (fr) Préparation cosmétique topique pour la peau et son procédé de production, composition contenant un sel d'acide gras supérieur d'ascorbyle -2-phosphate-6- et un tensioactif non ionique
JP5793056B2 (ja) 化粧料
JP2019055926A (ja) 美白化粧料組成物
JP2005132828A (ja) 外用組成物
WO2012169345A2 (fr) Préparation cutanée externe et son procédé de production
JP2001270828A (ja) 尋常性座瘡予防治療外用剤及びその外用剤を配合した化粧料
JP7352392B2 (ja) 外用組成物
JP2019077675A (ja) ジェル状皮膚外用剤又は皮膚化粧料
JP2019014703A (ja) リノール酸含有組成物
JP6209350B2 (ja) ニキビ抑制用組成物、皮膚外用剤及び化粧料
JP2019085333A (ja) 皮膚外用剤又は化粧料
JP7467037B2 (ja) 外用組成物
JP7356826B2 (ja) 外用組成物
EP4173612A1 (fr) Compositions appropriées pour une utilisation dans les soins de la peau
JP2016088859A (ja) 外用クリーム
JP5856766B2 (ja) 皮膚外用剤およびその製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12741110

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12741110

Country of ref document: EP

Kind code of ref document: A1